Text Size

Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01520246
First received: January 26, 2012
Last updated: January 28, 2012
Last verified: January 2012
History of Changes

January 26, 2012
January 28, 2012
January 2012
March 2012   (final data collection date for primary outcome measure)
  • PDLIM2 expression patterns in cancer and control tissues [ Designated as safety issue: No ]
  • 8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01520246 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Signaling in Tumorigenesis and Immunity

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.

OBJECTIVES:

  • To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control.

OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Leukemia
  • Lymphoma
  • Genetic: gene expression analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
Not Provided
March 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Specimens (e.g., tissue, blood, and bodily fluids) of various cancer cells and or tissues from de-identified patients such as T-cell acute lymphoblastic leukemia (T-ALL)
  • Normal control tissue

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01520246
CDR0000723902, COG-AALL12B2
Not Provided
Peter C. Adamson, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Gutian Xiao, MD University of Pittsburgh
National Cancer Institute (NCI)
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP